Accessibility Log In Help Join The Motley Fool

David Haen

XMFHaen

Recent Articles by David Haen

GettyImages-1083510246

May 30, 2020 by David Haen

Is Pfizer a Great Dividend Stock?

A strategic transaction this year will give investors two shots to earn dividends.

GettyImages-664386084

May 29, 2020 by David Haen

Now’s the Time to Buy These 3 Stocks

These drug developers will give your portfolio a boost.

GettyImages-187921657

May 24, 2020 by David Haen

3 Top Pharma Stocks to Buy Right Now

Promising new drugs will drive these companies' stocks skyward.

GettyImages-1133974061

May 22, 2020 by David Haen

Should You Own This Sleeper Biotech Stock?

This cancer-fighting biotech could have two approved drugs in the next year, and a whole lot more.

GettyImages-1138937146

May 19, 2020 by David Haen

Where Will Adaptimmune Be in 5 Years?

Big pharma partners could help this cutting-edge cell-therapy company be successful in the future.

GettyImages-1216472651

May 14, 2020 by David Haen

Will GenMark Diagnostics' Stock Keep Rising?

A coronavirus diagnostic test is fueling this biotech's revenue for 2020.

GettyImages-864446614

May 14, 2020 by David Haen

This Under-the-Radar Drug Developer May Have an Answer for Patients With Severe COVID-19

Third-quarter results from a COVID-19 trial could send this stock soaring.

GettyImages-1201544365

May 10, 2020 by David Haen

Is There A Safer Way to Invest in a Coronavirus Vaccine?

Size may matter in the long run.

GettyImages-1169106100

May 9, 2020 by David Haen

Is Axsome Therapeutics a Screaming Buy?

Two positive late-stage clinical trials may just be the beginning.

GettyImages-1129797106

May 9, 2020 by David Haen

If You Invested $10,000 in Amarin's IPO, This Is How Much Money You'd Have Now

Not all IPO returns are equal.

GettyImages-187921657

May 4, 2020 by David Haen

Should You Buy Global Blood Therapeutics Before This Week's Earnings?

On Wednesday, investors will learn the progress of its sickle cell disease drug launch.

GettyImages-508544108

May 2, 2020 by David Haen

AstraZeneca Notches Win with Prostate Cancer Drug

New clinical trial results may lead to a label expansion this quarter for Lynparza, and huge revenue growth for the drug.

GettyImages-1142997722

May 1, 2020 by David Haen

Did Merck Just Receive a Gift From the FDA?

A new, more convenient dosing schedule favors Keytruda.

GettyImages-536688016

Apr 30, 2020 by David Haen

Better Buy: Illumina vs. Adaptive Biotechnologies

One company has a well-established line of products that made it the leader in its niche, but the other has a bold vision about how to use them.

GettyImages-1207501947

Apr 29, 2020 by David Haen

Should You Buy Stock Now in This New Coronavirus Drug Developer?

This company's repurposed cancer drug might help patients with severe COVID-19.

GettyImages-618344178

Apr 28, 2020 by David Haen

Will Last Week's Biotech IPO Outperform in a Recession?

This cancer drug developer will have smooth sailing ahead -- at least until it reports clinical trial results next year.

GettyImages-1162987377

Apr 26, 2020 by David Haen

Myovant Squares Off with AbbVie On Endometriosis Treatment

With positive clinical trial results and a confirmatory study expected to report this quarter, investors should dig in.

GettyImages-1219784934

Apr 24, 2020 by David Haen

Better Buy: AnaptysBio vs. Exelixis

Key clinical trial results this quarter will determine the better buy.

GettyImages-1129797106

Apr 23, 2020 by David Haen

These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?

These companies just raised significant cash to advance promising drug pipelines.

GettyImages-1096306446

Apr 21, 2020 by David Haen

Could CVS Health Be a Millionaire-Maker Stock?

Investors seek to capitalize on one of the broadest-reaching companies in healthcare.

HOW THE MOTLEY FOOL CAN HELP YOU

Motley Fool Returns

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns

462%

S&P 500 Returns

125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/23/2023.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Chart Showing the Cumulative Growth of a $10,000 Investment in Stock Advisor

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services